AVEO Pharmaceuticals, Inc. (AVEO)

1.01
0.09 8.18
NASDAQ
Prev Close 1.10
Open 1.05
Day Low/High 1.00 / 1.11
52 Wk Low/High 0.56 / 3.59
Volume 4.37M
Exchange NASDAQ
Shares Outstanding 160.74B
Market Cap 176.81M
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: AVI, Aveo, Spectrum

Biotech Stock Mailbag: AVI, Aveo, Spectrum

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

AVEO Pharmaceuticals, Inc. Announces Timing For First Quarter Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. Announces Timing For First Quarter Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company's first quarter ended March 31, 2012 will be released before the market opens on Thursday, May 3, 2012.

AVEO Announces Publication Of Positive Tivozanib Phase 2 Clinical Trial Results In Journal Of Clinical Oncology

AVEO Announces Publication Of Positive Tivozanib Phase 2 Clinical Trial Results In Journal Of Clinical Oncology

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported results from a successful Phase 2 clinical trial evaluating the efficacy and safety of tivozanib in 272 patients with advanced renal ...

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) hit a new 52-week low Wednesday as it is currently trading at $11.22, below its previous 52-week low of $11.28 with 36,912 shares traded as of 10:10 a.m. ET. Average volume has been 272,200 shares over the past 30 days.

AVEO Pharmaceuticals Inc. Stock Downgraded (AVEO)

AVEO Pharmaceuticals Inc. Stock Downgraded (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) has been downgraded by TheStreet Ratings from from a hold to sell.

Data On AVEO Pharmaceuticals’ Tivozanib And AV-203 To Be Presented At AACR Annual Meeting 2012

Data On AVEO Pharmaceuticals’ Tivozanib And AV-203 To Be Presented At AACR Annual Meeting 2012

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three...

7 Cancer Drug Stocks to Know Right Now

7 Cancer Drug Stocks to Know Right Now

A first look at the cancer drug stocks that could run up in value as we get closer to the big ASCO conference.

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) hit a new 52-week low Monday as it is currently trading at $12.36, below its previous 52-week low of $12.42 with 134,988 shares traded as of 12:39 p.m. ET. Average volume has been 306,900 shares over the past 30 days.

Next Big Thing in Biotech: Cancer Drug Stocks

Next Big Thing in Biotech: Cancer Drug Stocks

Senior columnist Adam Feuerstein explains why cancer drug stocks are the next big thing in biotech.

AVEO Pharmaceuticals To Present At The Cowen And Company 32nd Annual Health Care Conference

AVEO Pharmaceuticals To Present At The Cowen And Company 32nd Annual Health Care Conference

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Cowen and Company 32 nd Annual Health Care Conference on Monday, March...

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) hit a new 52-week low Tuesday as it is currently trading at $12.92, below its previous 52-week low of $13 with 446,169 shares traded as of 2:40 p.m. ET. Average volume has been 306,900 shares over the past 30 days.

AVEO Reports 2011 Financial Results And Highlights Fourth Quarter Progress

AVEO Reports 2011 Financial Results And Highlights Fourth Quarter Progress

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today reported consolidated 2011 financial results and reviewed key progress achieved with its tivozanib and ficlatuzumab development programs in the fourth quarter of 2011.

AVEO Pharmaceuticals, Inc. Announces Timing For Fourth Quarter And Year-End 2011 Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. Announces Timing For Fourth Quarter And Year-End 2011 Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2011 will be released before the market opens on Tuesday, February 14, 2012.

AVEO Pharmaceuticals To Present At Several Upcoming Investment Conferences

AVEO Pharmaceuticals To Present At Several Upcoming Investment Conferences

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that members of the company’s management team are scheduled to present a corporate overview at several upcoming investment conferences.

J.P. Morgan Biotech Confab Live Chat

J.P. Morgan Biotech Confab Live Chat

TheStreet's Adam Feuerstein will give his impressions of the J.P. Morgan Healthcare Conference and answer readers' biotech investing questions.

AVEO Rises On Unusually High Volume (AVEO)

AVEO Rises On Unusually High Volume (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) is trading at unusually high volume Wednesday with 901,612 shares changing hands. It is currently at four times its average daily volume and trading up 39 cents (+2.8%).

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) is trading at unusually high volume Tuesday with 1.6 million shares changing hands. It is currently at seven times its average daily volume and trading down $2.80 (-16.3%).

Aveo Beats Onyx in Study of Dueling Kidney Cancer Drugs But Shares Still Fall

Aveo Beats Onyx in Study of Dueling Kidney Cancer Drugs But Shares Still Fall

Aveo will seek approval for its kidney cancer drug based on positive results from a late-stage study.

Stocks to Watch: Chesapeake, BP, Sears

Stocks to Watch: Chesapeake, BP, Sears

Chesapeake Energy and EnerVest will get $2.3 billion from France's Total for a 25% stake in a joint venture for oil drilling in the Utica Shale area of Ohio.

AVEO Pharmaceuticals, Inc. Announces Webcast And Conference Call

AVEO Pharmaceuticals, Inc. Announces Webcast And Conference Call

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Tuesday, January 3, 2012 at 8:30 a.

AVEO Pharmaceuticals To Present At The 30th Annual J.P. Morgan Healthcare Conference

AVEO Pharmaceuticals To Present At The 30th Annual J.P. Morgan Healthcare Conference

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 30 th Annual J.

AVEO Announces Patient Enrollment In Phase 2 Clinical Trial Of Tivozanib In Combination With MFOLFOX6 In Patients With Advanced Colorectal Cancer

AVEO Announces Patient Enrollment In Phase 2 Clinical Trial Of Tivozanib In Combination With MFOLFOX6 In Patients With Advanced Colorectal Cancer

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination ...

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade higher from current levels.

AVEO Pharmaceuticals And Boehringer Ingelheim Announce Manufacturing Agreement For Ficlatuzumab

AVEO Pharmaceuticals And Boehringer Ingelheim Announce Manufacturing Agreement For Ficlatuzumab

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO’s ...

AVEO To Present Tivozanib Clinical Data At Upcoming Oncology Medical Congresses

AVEO To Present Tivozanib Clinical Data At Upcoming Oncology Medical Congresses

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported clinical data evaluating its lead product candidate tivozanib will be featured at the 3 rd European Multidisciplinary Meeting on...

AVEO Pharmaceuticals Reports Third Quarter 2011 Financial Results

AVEO Pharmaceuticals Reports Third Quarter 2011 Financial Results

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated financial results for the third quarter of 2011 and provided an update on the tivozanib clinical program.

AVEO Pharmaceuticals, Inc. Announces Timing For Third Quarter 2011 Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. Announces Timing For Third Quarter 2011 Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company’s third quarter ended September 30, 2011 will be released before the market opens on Wednesday, November 2, 2011.

AVEO Pharmaceuticals Inc. Stock Upgraded (AVEO)

AVEO Pharmaceuticals Inc. Stock Upgraded (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) has been upgraded by TheStreet Ratings from a sell to hold.

AVEO Pharmaceuticals Inc. Stock Downgraded (AVEO)

AVEO Pharmaceuticals Inc. Stock Downgraded (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) has been downgraded by TheStreet Ratings from from a hold to sell.

TheStreet Quant Rating: D- (Sell)